[1] Rundfeldt, C.; Netzer, R. Neurosci. Lett. B, 282, 73-76.2000
[2] Wickenden, A.D.; Yu, W.; Zou, A.; Jeqla, T.; Waqoner, P.K. Mol. Pharmacol. 2000, 58, 591-600.
[3] Main, M.J.; Cryan, J.E.; Dupere, J.R.; Cox, B.; Clare, J.J.; Burbidge, S.A. Mol. Pharmacol. 2000, 58, 253-262.
[4] Delmas, P.; Brown, D.A. Nat. Rev. Neurosci. 2005, 6, 850-862.
[5] Wuttke, T.V.; Seebohm, G.; Bail, S.; Maljevic, S.; Lerche, H. Mol. Pharmacol. 2005, 67, 1009-1017.
[6] Maljevic, S.; Wuttke, T.V.; Seebohm, G.; Lerche, H. Pflugers. Arch-Eur. J. Physiol. 2010, 460, 277-288.
[7] Otto, J.F.; Kimball, M.M.; Wilcox, K.S. Mol. Pharmacol. 2002, 61, 921-927.
[8] Bialer, M.; White, H.S. Nat. Rev. Drug Discov. 2010, 9, 68-82.
[9] EMA. Ritigabine [EB/OL]. [2011-03-29]. http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/001245/WC500104835.pdf
[10] FDA. Ezogabine [EB/OL]. [2011-06-10]. http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/022345s 000lbl. pdf
[11] Kapetanovic, I.M.; Yonekawa, W.D.; Kupferberg, H.J. Epilepsy Res. 1995, 22, 167-173.
[12] Rundfeldt, C., Netzer, R. Arzneimittelforschung. 2000, 50, 1063-1070.
[13] Douša, M.; Srbek, J.; Rádl, S.; Cerný, J.; Klecán, O.; Havlíček, J.; Tkadlecová, M.; Pekárek, T.; Gibala, P.; Nováková, L. J. Pharma. Biomed. Anal. 2014, 94, 71-76.
[14] Knebel, N.G.; Grieb, S.; Leisenheimer, S.; Locher, M. J. Chromatogr. B. 2000, 748, 97-111. |